Related Experiment Videos
Polymorphonuclear leucocyte transfusion in neonatal septicaemia
Archives of Disease in Childhood
|December 1, 1983
Summary
Antibiotic-resistant septicaemia in newborns was treated with polymorphonuclear leucocyte infusions. While some infants survived, others did not, with no identified side effects from this novel treatment.
Area of Science:
- Neonatal Medicine
- Hematology
- Infectious Diseases
Background:
- Neonatal intensive care units (NICUs) face challenges with antibiotic-resistant infections.
- Septicaemia poses a significant mortality risk in premature infants.
- Limited treatment options exist for multidrug-resistant neonatal infections.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous polymorphonuclear leucocyte (PMN) infusions.
- To explore an alternative therapeutic strategy for antibiotic-resistant neonatal septicaemia.
Main Methods:
- A case series of 6 infants with resistant septicaemia in an NICU.
- Treatment involved intravenous infusions of PMN concentrate.
- Infants' clinical outcomes, including survival and complications, were monitored.
Main Results:
- Three out of six infants with resistant septicaemia survived the treatment.
- The surviving infants experienced no identified complications.
- No adverse side effects were reported during or after PMN infusions.
Conclusions:
- Intravenous PMN infusions represent a potential therapeutic option for severe, antibiotic-resistant neonatal septicaemia.
- This treatment approach warrants further investigation in larger studies.
- PMN therapy demonstrated an acceptable safety profile in this small cohort.